Press Releases
Sep 21, 2021

Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...

Sep 17, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today ahead of the European Society for Medical Oncology (ESMO)...

Sep 14, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on...

EXPLORE ALL US PRESS RELEASES

Articles
Aug 4, 2021

Astellas is committed to partnering with national and local non-profit organizations to help improve access to healthcare for underserved groups in the United States. In Fiscal Year 2020, the...

Jul 14, 2021

Improved score marks continuing effort in growing inclusive culture to support people with disabilities For the second year in a row, Astellas has been included in the Disability Equality Index as...

Jun 15, 2021

Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products